Want to see BFRI full AI Analyst Report?

Biofrontera (BFRI) Price & Analysis

214 Followers

BFRI Stock Chart & Stats

$0.74

$0.09(8.11%)

At close: Jan 08 4:00 PM EST

$0.74

$0.09(8.11%)

Day’s Range― - ―

52-Week Range$0.55 - $1.21

Previous CloseN/A

Volume12.39M

Average Volume (3M)249.99K

Market Cap

$14.21M

Enterprise Value$10.85

Total Cash (Recent Filing)$6.32M

Total Debt (Recent Filing)$7.72M

Price to Earnings (P/E)―

Beta0.91

Next Earnings

Aug 07, 2026

EPS Estimate

-0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.12

Shares Outstanding12,803,344

10 Day Avg. Volume217,442

30 Day Avg. Volume249,992

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.55

Price to Sales (P/S)0.14

P/FCF Ratio-0.43

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$6.00

Price Target Upside710.81% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.18

Revenue Forecast (FY)$46.10M

Bulls Say, Bears Say

Bulls Say

Clinical Trial ReadoutsData from the Phase 3 extremities trial and the Phase 2b acne trial expected early in 2026 could validate new indications and materially expand commercial opportunity.

Operational Cost SavingsRestructuring of agreements with former parent Biofrontera AG is expected to deliver cost savings and operational efficiencies that improve margins and cash flow flexibility.

Regulatory FilingA supplemental NDA submission for the extremities indication projected in mid-2026 could enable label expansion and broader prescribing, supporting future revenue growth.

Bears Say

Demand Timing VolatilityCustomer stockpiling ahead of an anticipated price increase could create a pull-forward effect, producing revenue volatility once the stocking period ends.

Profitability PressureA larger-than-planned net loss underscores ongoing profitability challenges that could weigh on the stock until margins show sustained improvement.

Top-line Momentum RiskIn-line quarterly revenue suggests limited top-line momentum, increasing the risk that growth expectations may not be met.

Biofrontera News

Biofrontera’s Acne PDT Trial Completion: What Investors Should Watch Next

Biofrontera, Inc. ($BFRI) announced an update on their ongoing clinical study. Biofrontera Inc. is advancing a Phase II...

10d ago

BFRI

Biofrontera’s Phase III Actinic Keratosis Study Nears Data Payoff for Investors

Biofrontera, Inc. ($BFRI) announced an update on their ongoing clinical study. Biofrontera Inc. is running a Phase III...

11d ago

BFRI

Biofrontera Shareholders Approve Director Elections and Equity Plan

Biofrontera ( ($BFRI) ) just unveiled an update. At its Annual Meeting of Stockholders held on June 11,...

1M ago

BFRI

Biofrontera Earnings Call Highlights Growth And Risks

Biofrontera, Inc. (($BFRI)) has held its Q1 earnings call. Read on for the main highlights of the call....

2M ago

BFRI

StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

AMT

BAP

Biofrontera downgraded to Speculative Buy from Buy at Benchmark

Benchmark analyst Bruce Jackson downgraded Biofrontera (BFRI) to Speculative Buy from Buy with a $3 price target after...

2M ago

BFRI

Is BFRI a Buy, Before Earnings?

Biofrontera, Inc. (BFRI) is scheduled to report 1st quarter earnings on 05/08/2026. Regarding Q1 estimates, Wall Street analysts...

2M ago

BFRI

Biofrontera Earnings Call: Profits Rise, Risks Remain

Biofrontera, Inc. (($BFRI)) has held its Q4 earnings call. Read on for the main highlights of the call....

4M ago

BFRI

Biofrontera reports Q4 revenue $17.1M vs. $12.6M last year

Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera (BFRI) Inc., stated: “2025 was a transformational year for...

4M ago

BFRI

Biofrontera, Inc. (BFRI) Q4 Earnings Cheat Sheet

Biofrontera, Inc. (BFRI) is scheduled to report 4th quarter earnings on 03/19/2026, after the market closes. Regarding Q4...

4M ago

BFRI

Biofrontera Reports Positive Phase 2b Acne Trial Results

An announcement from Biofrontera ( ($BFRI) ) is now available. On March 9, 2026, Biofrontera Inc. announced positive...

4M ago

BFRI

Biofrontera reports Phase 2b results of Ameluz PDT in acne vulgaris

Biofrontera (BFRI) announced results of its Phase 2b clinical trial evaluating Ameluz topical gel, 10% PDT for the...

4M ago

BFRI

Biofrontera Wins Key PTAB Ruling in Sun Patent Dispute

Biofrontera ( ($BFRI) ) has shared an announcement. On February 23, 2026, the U.S. Patent Trial and Appeal...

5M ago

BFRI

Biofrontera reports USPTO decision on Sun Pharma’s challenged claims

Biofrontera (BFRI) announced that on February 23, 2026, the U.S. Patent Trial and Appeal Board issued a Final...

5M ago

BFRI

BFRI FAQ

What was Biofrontera, Inc.’s price range in the past 12 months?

Biofrontera, Inc. lowest stock price was $0.55 and its highest was $1.21 in the past 12 months.

What is Biofrontera, Inc.’s market cap?

Biofrontera, Inc.’s market cap is $14.21M.

When is Biofrontera, Inc.’s upcoming earnings report date?

Biofrontera, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 20 days.

How were Biofrontera, Inc.’s earnings last quarter?

Biofrontera, Inc. released its earnings results on May 14, 2026. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.115 by -$0.295.

Is Biofrontera, Inc. overvalued?

According to Wall Street analysts Biofrontera, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Biofrontera, Inc. pay dividends?

Biofrontera, Inc. does not currently pay dividends.

What is Biofrontera, Inc.’s EPS estimate?

Biofrontera, Inc.’s EPS estimate is -0.11.

How many shares outstanding does Biofrontera, Inc. have?

Biofrontera, Inc. has 12,803,344 shares outstanding.

What happened to Biofrontera, Inc.’s price movement after its last earnings report?

Biofrontera, Inc. reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.115. Following the earnings report the stock price went up 3.024%.

Which hedge fund is a major shareholder of Biofrontera, Inc.?

Currently, no hedge funds are holding shares in BFRI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Biofrontera, Inc.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Biofrontera (BFRI) Earnings & Revenues

Historic Earnings Reports

BFRI Stock 12 Month Forecast

Average Price Target

$6.00

▲(710.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","-1":"-$1","1.75":"$1.75","4.5":"$4.5","7.25":"$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.01,1.6246153846153848,2.2392307692307694,2.8538461538461544,3.468461538461539,4.0830769230769235,4.697692307692308,5.312307692307693,5.926923076923077,6.541538461538462,7.156153846153846,7.770769230769231,8.385384615384616,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.01,1.393846153846154,1.7776923076923077,2.161538461538462,2.5453846153846156,2.9292307692307693,3.313076923076923,3.6969230769230768,4.0807692307692305,4.464615384615384,4.848461538461538,5.232307692307692,5.616153846153846,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.01,1.1630769230769231,1.3161538461538462,1.4692307692307693,1.6223076923076922,1.7753846153846156,1.9284615384615384,2.081538461538462,2.2346153846153847,2.3876923076923076,2.540769230769231,2.6938461538461542,2.846923076923077,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.688,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.81,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.57,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.896,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.924,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.954,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >